Publication | Closed Access
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
34
Citations
23
References
2020
Year
ThrombosisMetabolic SyndromeDiabetes ManagementCardiovascular DiseaseMedicinePlasminogen ActivatorDiabetesInsulin ManagementType 2FibrinolysisVascular BiologyDiabetes MellitusPlasma ConcentrationMicrovascular DysfunctionPharmacologyAtherosclerosis
| Year | Citations | |
|---|---|---|
Page 1
Page 1